HeartBeam, Inc. acquired substantially all assets of LIVMOR, Inc.
March 13, 2023
Share
HeartBeam, Inc. (NasdaqCM:BEAT) acquired substantially all assets of LIVMOR, Inc. In February 2023. The deal includes LIVMORâs intellectual property for an undisclosed amount, including 3 issued United States patents, LIVMOR technology, including the Halo AF Detection System, LIVMORs business contracts and relationships as well as all Samsung watch and tablet inventory. Additionally, HeartBeam hired LIVMORâs key technical employees.
HeartBeam, Inc. (NasdaqCM:BEAT) completed the acquisition of substantially all assets of LIVMOR, Inc. In February 2023.
HeartBeam, Inc. is a cardiac technology company. The Company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The Company is engaged in the development of its proprietary and patented Vector Electrocardiography (VECG) technology platform. Its VECG is capable of developing three-dimensional vector images of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It has two patented products in development, such as HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack. HeartBeam AIMIGo is a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.